ALDERLEY PARK, LONDON: BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces that the United States Patent and Trademark Office (USPTO) has granted a patent providing broad protection for the company’s lead asset, BVX001.
The claims granted within this patent (patent number US11,732,040), which belongs to the wider patent family “Therapy” currently being prosecuted in eight territories worldwide, provides ultimate broad protection for the lead therapeutic asset, BVX001, at the antigen level.
Tiffany Thorn, CEO of BiVictriX commented: “I am excited to announce that our first patent has been granted in the United States. This patent relates to our broadest patent family, providing robust protection for BVX001 at the antigen level, across multiple cancer types, and acts as a key milestone for the Company demonstrating the breadth of patent protection we can achieve with the Bi-Cygni® approach. This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio.
Barbara Fleck, European Patent Attorney and Partner at Appleyard Leads IP LLP commented: “I am very pleased to see that the USPTO has issued BiVictriX’s patent with broad claims to methods for treating a CD7+CD33+ haematological malignancy by administering a cell inhibiting agent linked to a cytotoxin that bispecifically binds to CD33 and CD7. Obtaining such broad claims in the antibody space is challenging and this not only validates BiVictriX’s Bi-Cygni® ADC technology for the treatment of AML, but also provides the Company with broad US patent coverage in a competitive space.”
BiVictriX and Abzena collaborate to manufacture antibody-drug conjugates